GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Can Fite BioPharma
Can-Fite is an Israeli biotech company. Its stock price is a classic example of a sector where the stock's trajectory is determined not by current earnings, but by the results of clinical trials of its drugs for the treatment of cancer and inflammatory diseases.
Share prices of companies in the market segment - General oncology therapy
Can-Fite BioPharma is an Israeli biopharmaceutical company developing oral drugs for the treatment of cancer and inflammatory diseases. We have classified it in the "General Oncology" segment. The chart below shows how investors value biotech companies with a broad pipeline.
Broad Market Index - GURU.Markets
Can-Fite BioPharma is an Israeli biopharmaceutical company developing small-molecule drugs for the treatment of cancer and inflammatory diseases. Its scientific advancements make it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how Can-Fite compares to it.
Change in the price of a company, segment, and market as a whole per day
CANF - Daily change in the company's share price Can Fite BioPharma
Can-Fite BioPharma Ltd.'s daily price change reflects the high volatility inherent in biotech companies. This indicator measures sensitivity to news about clinical trials of its drugs for the treatment of cancer and inflammatory diseases.
Daily change in the price of a set of shares in a market segment - General oncology therapy
Can-Fite BioPharma is an oncology company whose shares fluctuate between press releases about clinical trials. The chart below shows the average daily volatility in this sector. It serves as a benchmark for understanding that sharp fluctuations are normal for CANF shares.
Daily change in the price of a broad market stock, index - GURU.Markets
Can-Fite BioPharma is an Israeli biotech company with a broad development pipeline. Its shares react to news across multiple clinical programs. This complex, multi-factor dynamic contributes uniquely to the overall volatility of the healthcare sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Can Fite BioPharma
Can-Fite BioPharma's year-to-date performance tells the story of its extensive yet risky pipeline. Its 12-month market cap is highly volatile and dependent on news about its drugs for liver cancer, psoriasis, and NASH. Its valuation is a bet that its unique mechanism of action will prove successful in at least one of these areas.
Annual dynamics of market capitalization of the market segment - General oncology therapy
Can-Fite BioPharma Ltd. is an Israeli late-stage biotech company with a diversified portfolio. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Can-Fite BioPharma, with its platform of drugs for the treatment of cancer and inflammation, represents a diversified biotech bet. Its performance relative to the market reflects investors' assessment of the overall chances of its developments. The success of even one drug could lead to explosive growth, outperforming the market.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Can Fite BioPharma
Can-Fite is an Israeli biopharmaceutical company with a broad pipeline. Its monthly performance is highly volatile and reflects the cumulative impact of news across its many clinical programs. Progress in any one of them can significantly impact its valuation.
Monthly dynamics of market capitalization of the market segment - General oncology therapy
Can-Fite BioPharma Ltd. is an Israeli clinical-stage biopharmaceutical company developing oral drugs for the treatment of cancer and inflammatory diseases. The dynamics of its sector, shown in the chart, reflect the risks of R&D. Against this backdrop, it is possible to assess the progress of its platform, targeting the A3 adenosine receptor, in clinical trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Can-Fite BioPharma is an Israeli biotech company. Its NASDAQ shares are driven by clinical trial news rather than U.S. market trends. The chart shows the high volatility typical of biotechs, whose value is a bet on the success of future drugs.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Can Fite BioPharma
Can-Fite BioPharma is an Israeli biopharmaceutical company with several drug candidates. Its weekly stock price is volatile and reflects expectations for its various clinical programs in oncology and inflammatory diseases.
Weekly dynamics of market capitalization of the market segment - General oncology therapy
Can-Fite BioPharma is a pharmaceutical company with a broad range of oncology developments. This chart helps investors understand how its portfolio impacts weekly stock performance compared to the sector. Does diversification smooth out volatility or create unpredictable movements?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Can-Fite BioPharma is a pharmaceutical company whose stock moves to the rhythm of news about clinical trials and partnerships. The chart clearly shows how its weekly performance is detached from the broader market, moving along its own unique trajectory.
Market capitalization of the company, segment and market as a whole
CANF - Market capitalization of the company Can Fite BioPharma
The Can-Fite BioPharma chart shows a long history of biotech development. This Israeli company's market cap reflects investor hopes for its platform of drugs for treating cancer and inflammatory diseases. It's a highly volatile curve driven by news of clinical trials.
CANF - Share of the company's market capitalization Can Fite BioPharma within the market segment - General oncology therapy
Can-Fite BioPharma is an Israeli biopharmaceutical company developing oral drugs for the treatment of cancer and inflammatory diseases. In the general oncology segment, its market capitalization reflects the potential of its platform targeting the A3 adenosine receptor. The company's market capitalization reflects the success of its late-stage clinical programs.
Market capitalization of the market segment - General oncology therapy
Can-Fite BioPharma is an Israeli biopharmaceutical company. How big is this market? The chart below shows the pulse of the general oncology sector. Its high volatility reflects both the enormous hopes for new drugs and the high risks associated with development and clinical trials.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Can-Fite BioPharma chart shows the long history of this Israeli biotech company developing drugs to treat cancer and inflammatory diseases. Its volatile market cap is a visualization of all the ups and downs associated with the results of numerous clinical trials. This is a chart of persistence.
Book value capitalization of the company, segment and market as a whole
CANF - Book value capitalization of the company Can Fite BioPharma
The book value of Israeli Can-Fite BioPharma is its tangible capital base, consisting of the rights to its pipeline of drug candidates and financial reserves for late-stage clinical trials. The chart below shows how this scientific and financial capital has changed.
CANF - Share of the company's book capitalization Can Fite BioPharma within the market segment - General oncology therapy
Can-Fite BioPharma is an Israeli biopharmaceutical company. Its tangible assets are research laboratories where its small-molecule drug platform is developed. The chart shows the share of this specialized R&D infrastructure the company controls in its therapeutic niche.
Market segment balance sheet capitalization - General oncology therapy
Can-Fite BioPharma is a biopharmaceutical company. Pharmaceuticals, as the chart shows, are knowledge- and capital-intensive. Can-Fite focuses on drug development, and its capital is its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Can-Fite's assets are not factories, but a scientific platform based on the study of the A3 adenosine receptor, aimed at developing oral drugs for the treatment of cancer and inflammatory diseases such as psoriasis. Its book value reflects its research capital.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Can Fite BioPharma
Can-Fite is an Israeli biotech company with a broad pipeline. Its market capitalization is the combined valuation of its drug candidates. The chart shows volatility associated with news from several clinical programs.
Market to book capitalization ratio in a market segment - General oncology therapy
Can-Fite BioPharma is an Israeli biotech company developing drugs to treat cancer and inflammatory diseases. Its value depends on the success of its clinical programs. The chart shows how investors value its scientific platform.
Market to book capitalization ratio for the market as a whole
Can-Fite BioPharma is a pharmaceutical company with a broad pipeline. Its valuation is the sum of expectations for each of its research areas. This chart illustrates how investors value a diversified approach in biotech, which reduces the risk of failure in a single project.
Debts of the company, segment and market as a whole
CANF - Company debts Can Fite BioPharma
Can-Fite BioPharma is an Israeli biopharmaceutical company with several drug candidates in development. Supporting a broad clinical trial pipeline requires ongoing funding. This chart shows how the company manages its funding needs to advance its research in oncology and inflammatory diseases.
Market segment debts - General oncology therapy
Can-Fite BioPharma is an Israeli biotech company in late-stage clinical development with several drug candidates. Funding multiple programs simultaneously requires significant resources. This chart shows its financial position and ability to bring its drugs to market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Can Fite BioPharma
Can-Fite BioPharma is an Israeli clinical-stage biopharmaceutical company. This chart shows its financial structure. For a company whose drugs have been in development for many years, debt is a significant risk factor. Everything depends on final regulatory approval.
Market segment debt to market segment book capitalization - General oncology therapy
Can-Fite BioPharma is an Israeli biopharmaceutical company with a broad pipeline of candidates for the treatment of cancer and inflammatory diseases. The chart shows the overall debt burden in the pharmaceutical industry, which helps assess how the company finances its numerous but risky clinical programs at various stages of development.
Debt to book value of all companies in the market
Can-Fite BioPharma is an Israeli biopharmaceutical company with several clinical-stage drug candidates. Developing a broad pipeline requires significant capital. This chart shows that the company relies almost exclusively on equity capital to finance its numerous and risky programs.
P/E of the company, segment and market as a whole
P/E - Can Fite BioPharma
For Can-Fite BioPharma, an Israeli biotech company, the P/E ratio is irrelevant. The company lacks stable profitability. Its valuation is determined by investors' faith in its scientific platform and the potential of its drug candidates for treating oncology and inflammatory diseases.
P/E of the market segment - General oncology therapy
Can-Fite BioPharma is an Israeli late-stage biopharmaceutical company developing small-molecule therapeutics for the treatment of cancer and inflammatory diseases. This chart shows the average valuation for the sector, providing investors with context for evaluating Can-Fite's portfolio and scientific approach.
P/E of the market as a whole
Can-Fite BioPharma is an Israeli biopharmaceutical company with a diversified pipeline. Its valuation reflects the combined potential of its programs. It is not tied to the general economic trends shown in this chart, but rather relies on research data across several areas.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Can Fite BioPharma
Can-Fite BioPharma is a late-stage biopharmaceutical company developing small-molecule drugs for the treatment of cancer and inflammatory diseases. This chart reflects investor expectations for the clinical trial results of its oral drugs. The valuation is contingent on potential approval and commercial success.
%20P%2FE%20Can%20Fite%20BioPharma&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Can-Fite-BioPharma&v=1772576350901 "Chart of the company's future (projected) P/E Can Fite BioPharma")
Future (projected) P/E of the market segment - General oncology therapy
Can-Fite BioPharma is an Israeli biopharmaceutical company developing oral drugs for the treatment of cancer and inflammatory diseases. Its valuation relative to other biotech companies reflects investor sentiment about its scientific platform, demonstrating how the market assesses the risks and potential rewards of its clinical programs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-General-oncology-therapy&v=1772576350917 "Future (projected) P/E graph of the market segment - General oncology therapy")
Future (projected) P/E of the market as a whole
Can-Fite BioPharma is an Israeli biopharmaceutical company with several clinical-stage drug candidates for the treatment of cancer and inflammatory diseases. This chart shows the overall risk appetite of investors. For biotechs with a broad, but not late-stage, portfolio, a positive environment is important for funding all areas of research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772576350924 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Can Fite BioPharma
Can-Fite BioPharma is an Israeli clinical-stage biopharmaceutical company developing small-molecule drugs for the treatment of cancer and inflammatory diseases. The financial indicators shown in the chart represent investments in its platform, which targets the specific receptor A3AR.
Profit of companies in the market segment - General oncology therapy
Can-Fite BioPharma is an Israeli company developing drugs for the treatment of cancer and inflammatory diseases. This chart shows overall profitability in the general oncology and immunology sector. It highlights the company's industry-wide challenges, such as clinical trials and competition.
Overall market profit
Can-Fite BioPharma is an Israeli biopharmaceutical company with a broad pipeline of drug candidates. Its success depends on the results of numerous clinical trials. For the company at this stage, the macroeconomic metrics reflected in this chart are irrelevant compared to scientific data.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Can Fite BioPharma
Can-Fite BioPharma is an Israeli biotech company with a broad pipeline in oncology and inflammatory diseases. Its future profit forecast is a cumulative assessment of the prospects of its drug candidates. This chart shows whether analysts believe its research and development pipeline will reach the commercial stage.
%20profit%20of%20the%20company%20Can%20Fite%20BioPharma&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Can-Fite-BioPharma&v=1772576351098 "Graph of future (projected) profit of the company Can Fite BioPharma")
Future (predicted) profit of companies in the market segment - General oncology therapy
Can-Fite BioPharma is an Israeli biopharmaceutical company developing small-molecule drugs for the treatment of cancer and inflammatory diseases. Their drugs target a specific receptor found on cancer cells. This graph shows prognoses for oncology. It illustrates how a targeted approach can lead to the creation of new treatments with improved safety profiles.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-General-oncology-therapy&v=1772576351161 "Graph of future (predicted) profits of companies in a market segment - General oncology therapy")
Future (predicted) profit of the market as a whole
For Can-Fite BioPharma, a company with several drugs in development, this schedule is important for investment appeal. An optimistic economic environment facilitates raising funds for parallel clinical trials. During downturns, investors may need to focus on the core business.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772576351263 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Can Fite BioPharma
Can-Fite BioPharma is an Israeli biotech company with several drugs in development. This chart represents investors' aggregate risk-adjusted valuation of the company's entire portfolio's potential revenue.
P/S market segment - General oncology therapy
Can-Fite BioPharma is an Israeli biopharmaceutical company developing small-molecule drugs for the treatment of cancer and inflammatory diseases. This chart shows the average valuation in the general oncology sector. It helps understand how investors view Can-Fite's scientific platform and development pipeline.
P/S of the market as a whole
Can-Fite BioPharma Ltd. is an Israeli biopharmaceutical company developing small-molecule drugs for the treatment of cancer and inflammatory diseases. The company's valuation is based on the potential of its pipeline of candidates. This chart, reflecting the valuation of companies with actual revenue, highlights the high risk nature of biotech.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Can Fite BioPharma
Can-Fite BioPharma is an Israeli biopharmaceutical company with several late-stage drugs for the treatment of cancer and inflammatory diseases. The company's valuation is a bet on the success of its platform. The chart shows how investors assess the likelihood of its drugs being approved.
%20P%2FS%20Can%20Fite%20BioPharma&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Can-Fite-BioPharma&v=1772576351586 "The graph of the company's future (projected) P/S Can Fite BioPharma")
Future (projected) P/S of the market segment - General oncology therapy
Can-Fite BioPharma is an Israeli biotech company developing small-molecule drugs for the treatment of cancer and inflammatory diseases such as psoriasis. Its drugs target a specific receptor, A3AR. This chart shows how investors view the potential of its scientific platform.
%20P%2FS%20market%20segment%20graph%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-General-oncology-therapy&v=1772576351596 "Future (projected) P/S market segment graph - General oncology therapy")
Future (projected) P/S of the market as a whole
This indicator summarizes expectations for the oncology market. For Can-Fite BioPharma, an Israeli company with a portfolio of drugs for the treatment of cancer and inflammatory diseases, it is an indicator of the investment climate. Market optimism allows it to continue clinical trials in several promising areas simultaneously.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772576351628 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Can Fite BioPharma
Can-Fite BioPharma is an Israeli biopharmaceutical company developing small-molecule drugs for the treatment of cancer and inflammatory diseases. This chart reflects revenue from licensing agreements. Future revenue is dependent on the success of clinical trials of its drugs targeting the specific A3AR receptor.
Sales of companies in the market segment - General oncology therapy
Can-Fite BioPharma is an Israeli biopharmaceutical company developing small-molecule drugs for the treatment of cancer and inflammatory diseases. This chart shows its financial activity in the general oncology sector. Can-Fite's platform is based on targeting the A3 adenosine receptor, a unique approach to drug development.
Overall market sales
Can-Fite BioPharma is an Israeli biopharmaceutical company developing drugs for the treatment of cancer and inflammatory diseases. Its development depends on successful clinical trials. The overall economic situation, shown in this chart, influences the availability of capital for R&D and the strategic decisions of major pharmaceutical partners.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Can Fite BioPharma
Can-Fite BioPharma is an Israeli biopharmaceutical company developing small-molecule drugs for the treatment of cancer and inflammatory diseases. Its pipeline targets the specific receptor A3AR. This chart reflects analyst assessments of the company's entire clinical pipeline and the potential of its scientific platform.
%20sales%20of%20the%20company%20Can%20Fite%20BioPharma&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Can-Fite-BioPharma&v=1772576351720 "Schedule of future (projected) sales of the company Can Fite BioPharma")
Future (projected) sales of companies in the market segment - General oncology therapy
Can-Fite BioPharma is a biopharmaceutical company developing small-molecule drugs for the treatment of cancer and inflammatory diseases. This chart shows expectations for the overall oncology therapeutics sector, providing context for assessing the potential market for the company's drugs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-General-oncology-therapy&v=1772576351750 "Schedule of future (projected) sales of companies in the market segment - General oncology therapy")
Future (projected) sales of the market as a whole
Can-Fite BioPharma Ltd. is an Israeli biopharmaceutical company developing small-molecule drugs for the treatment of cancer and inflammatory diseases. Its valuation is determined by progress in clinical trials. This graph, reflecting the overall state of the economy, influences investor risk appetite, which is important for funding clinical-stage biotech companies.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772576351787 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Can Fite BioPharma
Can-Fite BioPharma is an Israeli biotech company with several drugs in clinical development for the treatment of cancer and inflammatory diseases. This chart shows that the company is in the investment phase. Future profitability depends on the success of its late-stage clinical trials.
Market segment marginality - General oncology therapy
Can-Fite BioPharma is a biopharmaceutical company developing small-molecule drugs for the treatment of cancer and inflammatory diseases. For a company in clinical trials, this chart serves as a benchmark. It shows the average profitability achieved by successful companies in their sector, illustrating the financial potential should their drugs be approved.
Market marginality as a whole
Can-Fite BioPharma is an Israeli biopharmaceutical company developing drugs for the treatment of cancer and inflammatory diseases. This total market return chart does not impact its operations. Its future depends on the results of late-stage clinical trials and its ability to commercialize its developments.
Employees in the company, segment and market as a whole
Number of employees in the company Can Fite BioPharma
Can-Fite BioPharma is an Israeli biopharmaceutical company developing small molecules for the treatment of cancer and inflammatory diseases. This graph shows a compact team managing a portfolio of clinical programs. Their size is typical for an R&D company.
Share of the company's employees Can Fite BioPharma within the market segment - General oncology therapy
Can-Fite BioPharma is an Israeli company developing small-molecule drugs for the treatment of cancer and inflammatory diseases. This chart shows the percentage of leading pharmacologists and clinicians working with A3 adenosine receptors that the company attracts. It reflects the concentration of its unique scientific expertise in its specific field.
Number of employees in the market segment - General oncology therapy
Can-Fite BioPharma is an Israeli biopharmaceutical company developing small-molecule drugs for the treatment of cancer and inflammatory diseases. This graph shows that pharmaceutical innovations are happening all over the world, and small research centers in countries like Israel are making a significant contribution to the advancement of global medicine, creating jobs for scientists.
Number of employees in the market as a whole
Can-Fite BioPharma is an Israeli company whose shares are traded in the US. This demonstrates how global the market for biopharmaceutical innovation and capital has become. The US labor market, reflected in this chart, is enriched by the attraction of foreign companies that open offices and conduct clinical trials here.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Can Fite BioPharma (CANF)
Can-Fite BioPharma is an Israeli biotech company. This chart is a classic example of intellectual capital valuation. The company's value is based on market expectations for its pipeline of drug candidates (e.g., Piclidenoson). The chart demonstrates the high future value the market is pricing into these diverse scientific developments.
%20of%20the%20company%20Can%20Fite%20BioPharma%20(CANF)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Can-Fite-BioPharma-CANF&v=1772576352005 "Chart of market capitalization per employee (in thousands of dollars) of the company Can Fite BioPharma (CANF)")
Market capitalization per employee (in thousands of dollars) in the market segment - General oncology therapy
Can-Fite BioPharma is an Israeli biotech company with a broad pipeline of developments in oncology and inflammatory diseases. The chart shows the average market perception of the potential of their various programs. This allows for a comparison of their diversified approach with more focused biotech companies.
%20by%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-General-oncology-therapy&v=1772576352034 "Market capitalization per employee (in thousands of dollars) by market segment - General oncology therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Can-Fite BioPharma Ltd. is an Israeli biopharmaceutical company with a broad pipeline. This chart reflects the average market value assigned to a single employee, allowing for the valuation of its diversified scientific platform.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772576352048 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Can Fite BioPharma (CANF)
Can-Fite BioPharma is an Israeli clinical-stage biotech company with no commercial products. This chart shows the net loss per employee, reflecting how much the company invests in each scientist for R&D.
%20Chart%20Can%20Fite%20BioPharma%20(CANF)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Can-Fite-BioPharma-CANF&v=1772576352082 "Company Profit Per Employee (in thousands of dollars) Chart Can Fite BioPharma (CANF)")
Profit per employee (in thousands of dollars) in the market segment - General oncology therapy
Can-Fite BioPharma is an Israeli biopharmaceutical company developing drugs for the treatment of cancer and inflammatory diseases. While in clinical trials, it is likely to report negative earnings per employee. This metric reflects the high investment in its scientific team and long-term research, which is typical in this industry.
%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-General-oncology-therapy&v=1772576352109 "Chart of profit per employee (in thousands of dollars) in the market segment - General oncology therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Can-Fite BioPharma (CANF) is an Israeli clinical-stage biotech company developing small-molecule drugs (Piclidenoson, Namodenoson) for the treatment of cancer and inflammatory diseases. This is an R&D business. This chart shows the market average dollar return per employee. For CANF (which is not yet profitable), this is a benchmark: in biotech, IP can significantly exceed this average.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772576352160 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Can Fite BioPharma (CANF)
Can-Fite BioPharma is an Israeli clinical-stage biopharmaceutical company. This graph reflects the long journey of drug development. Low or zero values are typical for a company's R&D and serve as a benchmark against which future commercial success will be measured if the drugs are approved.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Can-Fite-BioPharma-CANF&v=1772576352191 "Sales chart per company employee Can Fite BioPharma (CANF)")
Sales per employee in the market segment - General oncology therapy
Can-Fite BioPharma is an Israeli clinical-stage biotech company developing drugs for the treatment of cancer and inflammatory diseases. Revenue is not yet available. This chart shows the average revenue per employee in the segment, which serves as a benchmark for commercial pharmaceutical companies.
Sales per employee for the market as a whole
Can-Fite BioPharma is an Israeli clinical-stage biotech company developing drugs for the treatment of cancer and inflammatory diseases. The company has no commercial revenue, which is irrelevant. Its entire value lies in the potential of its R&D platform.
Short shares by company, segment and market as a whole
Shares shorted by company Can Fite BioPharma (CANF)
Can-Fite BioPharma is an Israeli biotech company with a long history of clinical failures in treating cancer and inflammation. This chart shows that investors are tired of believing. The bears are betting that their current developments (Piclidenoson, Namodenoson) will suffer the same fate as their previous ones—failure in trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Can-Fite-BioPharma-CANF&v=1772576352315 "Short Shares Chart for the Company Can Fite BioPharma (CANF)")
Shares shorted by market segment - General oncology therapy
Can-Fite BioPharma is an Israeli biopharmaceutical company developing small-molecule drugs for the treatment of cancer (liver) and inflammatory diseases (psoriasis). This chart reflects the total volume of short positions in the biotech sector. High values indicate general investor skepticism about the success of risky clinical trials in oncology.
Shares shorted by the overall market
Can-Fite BioPharma is an Israeli clinical-stage biotech developing drugs to treat cancer and inflammatory diseases. This chart reflects the general fear. When investors are afraid, they avoid stocks with dual risks: scientific (trial failure) and geopolitical (Israel). CANF falls victim to risk aversion as panic mounts in the market.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Can Fite BioPharma (CANF)
Can-Fite BioPharma is an Israeli biotech company developing drugs for cancer and inflammatory diseases (such as psoriasis). This chart tracks how investors react to binary events—FDA decisions and trial data—by showing "overheated" (above 70) in anticipation of approval or "oversold" (below 30) after a rejection.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Can-Fite-BioPharma-CANF&v=1772576352381 "RSI 14 indicator chart for the company's stock Can Fite BioPharma (CANF)")
RSI 14 Market Segment - General oncology therapy
Can-Fite BioPharma is an Israeli biotech company developing small-molecule drugs (based on the A3AR receptor) for the treatment of cancer and inflammatory diseases (psoriasis). This chart measures the collective excitement in the oncology biotech sector. It helps determine whether the entire speculative segment is oversold.
RSI 14 for the overall market
For Can-Fite BioPharma, a biotech in R&D, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is turned off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CANF (Can Fite BioPharma)
Can-Fite BioPharma is an Israeli biotech company developing oral drugs (Piclidenoson, Namodenoson) for the treatment of cancer and inflammatory diseases. This chart shows the average analyst forecast. Their targets are based on clinical trial results (e.g., for liver cancer) and regulatory prospects.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CANF-Can-Fite-BioPharma&v=1772576352703 "A chart showing analyst consensus forecasts for the expected stock price. CANF (Can Fite BioPharma)")
The difference between the consensus estimate and the actual stock price CANF (Can Fite BioPharma)
Can-Fite is an Israeli biotech company developing oral drugs (based on A3AR) for the treatment of liver cancer and inflammatory diseases. This chart shows the upside and downside potential analysts see for the stock. It measures the gap between the price and forecast, reflecting their confidence in this R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CANF-Can-Fite-BioPharma&v=1772576352753 "A chart showing the difference between the consensus forecast and the actual stock price. CANF (Can Fite BioPharma)")
Analyst consensus forecast for stock prices by market segment - General oncology therapy
Can-Fite BioPharma is an Israeli biotech company developing small-molecule drugs (tablets) for the treatment of liver cancer and inflammatory diseases. This chart shows general expectations for the general oncology sector. It reflects experts' confidence in the company's R&D pipeline.
Analysts' consensus forecast for the overall market share price
Can-Fite BioPharma (CANF) is an Israeli clinical-stage biopharmaceutical company developing small molecules for the treatment of cancer and inflammatory diseases (psoriasis). This is high-risk R&D. This chart shows the overall risk appetite in the market and is an indicator of the "open" or "closed" funding window for speculative biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Can Fite BioPharma
Can-Fite is an Israeli clinical-stage biotech company. Their R&D platform is based on A3AR, a specific receptor they claim is involved in inflammation and cancer, allowing them to treat everything from psoriasis to liver cancer. This graph is a clear indicator of their R&D. It reflects their (very long) journey, their clinical data, and the market's confidence in their versatile approach.
AKIMA Market Segment Index - General oncology therapy
Can-Fite BioPharma (CANF) is an Israeli biotech company whose scientific strategy is built on a single target—the A3AR receptor. They are developing drugs (Piklidezone, NamOden) for the treatment of inflammation (psoriasis) and cancer. This chart shows the average index for the segment. It helps assess how this platform R&D strategy compares to the average.
The AKIM Index for the overall market
Can-Fite BioPharma is an Israeli biopharmaceutical company developing small molecules for the treatment of cancer, liver disease, and inflammation. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this long-running scientific story compares to overall economic trends.
